Canagliflozin or acarbose versus placebo to ameliorate post‐bariatric hypoglycaemia – The HypoBar I randomized clinical trial protocol
Study context
- Population
- Subjects with post-bariatric hypoglycaemia (PBH), mostly after RYGB
- Planned comparison
- Canagliflozin vs acarbose vs placebo
Methodological detailsdouble-blinded, crossover, Outcomes: effectiveness in reducing PBH risk, safety, ambulatory glucose profile and entero-endocrine responses during a 4-week intervention period
- Double-blinded
- Crossover
- Outcomes: effectiveness in reducing PBH risk, safety, ambulatory glucose profile and entero-endocrine responses during a 4-week intervention period
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Canagliflozin or acarbose versus placebo to ameliorate post‐bariatric hypoglycaemia – The HypoBar I randomized clinical trial protocol. Diabet Med. Published 29 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →